Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:39 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 33,075 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: placebo Clear all
Completed Phase 3 Interventional

Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension

NCT00080457
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
sitaxsentan sodium
Drug
Lead sponsor
Encysive Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 9, 2007 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Not applicable Interventional Results available

Lidocaine Analgesia For Removal Of Wound Vac Dressings

NCT01126359
View directory record Official record
Conditions
Pain
Interventions
Lidocaine, Placebo-Saline
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Oct 21, 2026, 5:39 AM EDT
Not listed Phase 3 Interventional

Buccal Prochlorperazine Versus Intravenous Prochlorperazine for Migraine Headaches, a RCT

NCT02779959
View directory record Official record
Conditions
Migraine Disorders
Interventions
Prochlorperazine
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Jan 5, 2018 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 4 Interventional Results available

The Effect of Dipeptidyl Peptidase 4 Inhibition on Growth Hormone Secretion in Women With Polycystic Ovarian Syndrome

NCT02122380
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Sitagliptin, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 8, 2020 · Synced Oct 21, 2026, 5:39 AM EDT
Withdrawn Phase 2 Interventional

Sphenopalatine Ganglion Block for the Treatment of Post-Stroke Headache

NCT05365880
View directory record Official record
Conditions
Headache, Stroke, Ischemic Stroke
Interventions
Liquid Lidocaine, Placebo
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Transabdominal Plane (TAP) Blocks for Inguinal Hernia Repairs

NCT05672680
View directory record Official record
Conditions
Inguinal Hernia
Interventions
0.25% Bupivacaine, Placebo, TAP block
Drug · Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 28, 2025 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 2 Interventional Results available

Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap

NCT02131662
View directory record Official record
Conditions
Leiomyoma
Interventions
BAY1002670, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
36
States / cities
Mesa, Arizona • Tucson, Arizona • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 21, 2026, 5:39 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Observational Study of Lyzme5 Impact on Cholesterol and Body Weight in Man

NCT01634646
View directory record Official record
Conditions
Overweight, Elevated Cholesterol
Interventions
Lyzme5
Dietary Supplement
Lead sponsor
Jeff Golini
Industry
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Billings, Montana
Source: ClinicalTrials.gov public record
Updated Jul 16, 2013 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 2 Interventional

ADX48621 for the Treatment of Levodopa Induced Dyskinesia in Patients With Parkinson's Disease

NCT01336088
View directory record Official record
Conditions
Parkinson's Disease
Interventions
ADX48621, Placebo
Drug
Lead sponsor
Addex Pharma S.A.
Industry
Eligibility
30 Years to 75 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
13
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2012 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Secukinumab in Mild Psoriasis

NCT03131570
View directory record Official record
Conditions
Psoriasis
Interventions
Secukinumab, Placebo followed by Secukinumab
Drug
Lead sponsor
James G. Krueger, MD, PhD
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Not applicable Interventional Results available

Response to Supplement and Placebo in GERD

NCT01915173
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD), Heartburn, Dyspepsia
Interventions
Supplement, Placebo, Expanded Interview, Standard Interview
Drug · Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety, Tolerability, and PK of MRX-8 Administered Intravenously to HVs in SAD and MAD Cohorts

NCT04649541
View directory record Official record
Conditions
Safety
Interventions
MRX-8, Placebo
Drug
Lead sponsor
MicuRx
Industry
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 3 Interventional

Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count

NCT00003805
View directory record Official record
Conditions
Bone Marrow Suppression, Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
piperacillin sodium, piperacillin-tazobactam, tazobactam sodium, vancomycin
Drug
Lead sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Network
Eligibility
2 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1997
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2012 · Synced Oct 21, 2026, 5:39 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

NCT06238466
View directory record Official record
Conditions
Cardiovascular
Interventions
AZD1705, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
98 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
5
States / cities
Glendale, California • Jacksonville, Florida • Winter Park, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Recruiting Phase 2 Interventional

A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

NCT07643766
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ENV-294, Placebo
Drug · Other
Lead sponsor
Enveda Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
Encinitas, California • Los Angeles, California • Northridge, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 3 Interventional Results available

A Study Of Milnacipran In Patients With Fibromyalgia: Effects On 24 Hour Ambulatory Blood Pressure Monitoring

NCT00618956
View directory record Official record
Conditions
Fibromyalgia
Interventions
Milnacipran hydrochloride, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
38
States / cities
Birmingham, Alabama • Phoenix, Arizona • Pismo Beach, California + 33 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2009 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Oxytocin and the Social Brain

NCT02393456
View directory record Official record
Conditions
Social Psychology
Interventions
Intranasal oxytocin, Intranasal placebo
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 30 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2017 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Not applicable Interventional Results available

Trial of Minocycline to Treat Children With Fragile X Syndrome

NCT01053156
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
minocycline hydrochloride, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
42 Months to 16 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Efficacy of Olibra: A 12 Week Controlled Trial

NCT01416051
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Olibra, Placebo
Dietary Supplement · Other
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 60 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Dec 18, 2015 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 3 Interventional

Primary Progressive Multiple Sclerosis (PPMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (PERSEUS)

NCT04458051
View directory record Official record
Conditions
Primary Progressive Multiple Sclerosis
Interventions
Tolebrutinib, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
45
States / cities
La Jolla, California • Los Alamitos, California • Los Angeles, California + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 4 Interventional Results available

Utility of Trimethoprim-sulfamethoxazole Use in Skin Abscess Management

NCT00679302
View directory record Official record
Conditions
Skin Diseases, Infectious
Interventions
Trimethoprim-sulfamethoxazole, Placebo group
Drug
Lead sponsor
St. Louis University
Other
Eligibility
3 Months to 18 Years
Enrollment
161 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 4, 2018 · Synced Oct 21, 2026, 5:39 AM EDT
Terminated Phase 4 Interventional Results available

Evaluation of Modafinil vs Placebo for Treatment of Anesthesia Delayed Emergence in Obstructive Sleep Apnea

NCT02494102
View directory record Official record
Conditions
Obstructive Sleep Apnea, Delayed Emergence From Anesthesia
Interventions
Modafinil, Placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2019 · Synced Oct 21, 2026, 5:39 AM EDT
Terminated Phase 2 Interventional Results available

Megestrol Acetate in Treating Weight Loss or Anorexia in Young Patients With Malignancies Who Are Undergoing Radiation Therapy and/or Chemotherapy

NCT01200602
View directory record Official record
Conditions
Anorexia, Weight Changes
Interventions
megestrol acetate, clinical observation
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 25, 2015 · Synced Oct 21, 2026, 5:39 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Acute Treatment Trial in Adult Subjects With Migraines

NCT03872453
View directory record Official record
Conditions
Migraine
Interventions
Zavegepant, Zavegepant matching placebo, Intranasal Aptar Pharma Unit Dose System
Drug · Device
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
82
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2023 · Synced Oct 21, 2026, 5:39 AM EDT